← Back

PFEPfizer

$27.72+0.25%Real quote · delayedPharmaPharma & biotech · 16 peers →

🏛️ Company factsSEC filings + FINRA official data

Annual revenue $62.6B · latest quarter up 2.6% YoY · profitable (FY net income $7.8B) · short activity above its recent average — bears adding.

FY revenue

$62.6B

2025-12

Latest Q YoY

+2.6%

FY net income

$7.8B

Diluted EPS

$1.37

Short volume

50.6%

20d avg 39.7% · shorts building

🐋 5%+ ownership filings (last 180d)

The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.

2026-05-01passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
2026-03-27passive (13G)VANGUARD GROUP INC

🎯 Market expectations

Expectation reliability Medium · 48/100

Nasdaq analyst consensus · the pre-news baseline

Next quarter (Sep 2026) consensus$0.79Estimate range $0.67 ~ $0.94 · 6 analysts

History: actual vs consensusavg +16.6%

Jun 2026$0.77 vs $0.68+13.24%
Mar 2026$0.75 vs $0.71+5.63%
Dec 2025$0.66 vs $0.57+15.79%
Sep 2025$0.87 vs $0.66+31.82%

The takeaway

This company habitually beats by +16.6% — the next report has to clear that bar to count as good news.

Analyst estimates, not our forecast · not investment advice

What's moving this stock lately

2 direct · 2 2nd-order · 0 thematic

Ranked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)

#1▲1.1%2nd-orderFDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults16d ago
As a Priovant JV partner and origin of the molecule, Pfizer holds indirect economic and commercial upside from the approval.
Impact chain →
Also named: ROIV · ARGX · OCGXY
#2▼0.34%DirectFDA Grants Accelerated Approval to a New Breast Cancer Treatment8d ago
Ibrance and its breast-cancer franchise could see marginal pressure from the new competing therapy.
Impact chain →
Also named: AZN · GILD · LLY
#3▼0.15%2nd-orderTuesday's First Moves: BE Joining SPX, AMGN & NVS Fall, PANW Downgrade4d ago
As a bellwether peer, Pfizer is indirectly dragged by the same wave of weaker risk appetite across large-cap pharma
Impact chain →
Also named: AMGN · NVS · PANW · CRWD · ZS · BE
#4▲0.15%DirectDividend Harvesting Portfolio Week 288: $28,800 Allocated, $3,289.51 In Projected Dividends4d ago
Named as a high-dividend pharma stock; sentiment-driven attention with no new fundamental catalyst
Impact chain →
Also named: AGNC · AVGO · ENB · MO

🕰️ Price × news · engine report card

Drag to pan, scroll to zoom · real daily bars and volume

The 29 engine calls on this chart (hit / miss / pending) are Pro — price and volume only for now▂ volume

📜 Call history (newest first

🔒 Pro only

29 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view

🔒 Pro only

Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.